[Epidemiology of Prostate Cancer from Three Centers and Analysis of the First-line Hormonal Therapy for the Advanced Disease]

Overview

Journal Zhonghua Wai Ke Za Zhi

Specialty General Surgery

Date 2008 Nov 28

PMID 19035151

Citations 14

Authors

Chun-Guang Ma

Ding-Wei Ye

Chang-Ling Li

Fang-Jian Zhou

Xu-Dong Yao

Shi-Lin Zhang

Bo Dai

Hai-Liang Zhang

Yao Zhu

Yi-Jun Shen

Affiliations

Soon will be listed here.

Abstract

Objectives: To analyze the epidemiology information of prostate cancer from three centers of Beijing, Shanghai, Guangzhou, and to reflect the current situation of prostate cancer in China, and to analyze the information of 272 patients with advanced prostate cancer who received hormonal therapy to find the prognostic factors of hormone therapy.

Methods: Collect the information of 525 patients with prostate cancer from three centers. Two hundred and seventy-two cases of advanced prostate cancer with full information were selected from the 525 cases to analyze the prognostic factors of hormone therapy.

Results: Three hundred and fifty-seven cases (68.0%) had advanced disease at diagnosis and 80.2% patients received hormone therapy as the main therapy. Prognostic analysis indicated that Gleason score, bone metastasis and prostate specific antigen nadir were independent prognostic factors of progression-free survival time.

Conclusions: In this report, most patients are advanced prostate cancer at diagnose, and hormonal therapy is the main therapy. Gleason score, bone metastasis, prostate specific antigen nadir are independent prognostic factors of advanced prostate cancer after hormone therapy.

Citing Articles

GILT stabilizes cofilin to promote the metastasis of prostate cancer.

Han D, Wu Z, Zhang C, Wei Z, Chao F, Xie X Cell Death Discov. 2025; 11(1):10.

PMID: 39820478 PMC: 11739388. DOI: 10.1038/s41420-025-02288-0.

Silencing of matrix metalloprotease-12 delays the progression of castration-resistant prostate cancer by regulating autophagy and lipolysis.

Zheng X, Xie X, Wang W, Wang L, Tan B Braz J Med Biol Res. 2024; 57:e13351.

PMID: 38511770 PMC: 10946229. DOI: 10.1590/1414-431X2024e13351.

Real-world analysis of apalutamide-associated skin rash in Chinese patients with prostate cancer.

Yang Z, Shao Y, Huang H, Liu Y, Wang Z, Wang Y World J Urol. 2024; 42(1):171.

PMID: 38506974 DOI: 10.1007/s00345-024-04880-y.

A Novel Nomogram for Identifying the Patients at Risk for Rapid Progression of Advanced Hormone-Sensitive Prostate Cancer.

Wu M, Pan C, He Y, Yang B Cancer Manag Res. 2023; 15:1015-1024.

PMID: 37746314 PMC: 10516215. DOI: 10.2147/CMAR.S425181.

Simultaneous thulium laser resection of the prostate and transperineal prostate biopsy in clinically diagnosed metastatic prostate cancer with bladder outlet obstruction.

Shi Y, Cao T, Xu J, Cui D, Wang X, Zhu Y Lasers Med Sci. 2023; 38(1):188.

PMID: 37596454 DOI: 10.1007/s10103-023-03848-5.